Back to Search
MONICA ARQUETTE, PHARMD
PHARMD
Pharmacist
NPI: 1558953497Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
I066721(NY)
Research & Publications (14)
A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing.
PMID 17289894·Clin Cancer Res·2007
3-trial
A phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer.
PMID 16328044·Oncol Rep·2006
3-trial
From dogs to frogs: how pets, laboratory animals, and wildlife aided in elucidating harmful effects arising from a hazardous dumpsite.
PMID 16179745·ILAR J·2005
6-review
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
PMID 16009949·J Clin Oncol·2005
3-trial
Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar.
PMID 15942626·Br J Cancer·2005
3-trial
Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies.
PMID 15534095·Clin Cancer Res·2004
3-trial
HER2 expression in salivary gland carcinomas: dependence on histological subtype.
PMID 14871971·Clin Cancer Res·2004
3-trial
Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies.
PMID 12879480·Cancer·2003
3-trial
Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group.
PMID 12743146·J Clin Oncol·2003
3-trial
Phase I study of rubitecan and gemcitabine in patients with advanced malignancies.
PMID 12419757·Ann Oncol·2002
3-trial
Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies.
PMID 12412177·Cancer·2002
3-trial
Holistic risk-based environmental decision making: a Native perspective.
PMID 11929736·Environ Health Perspect·2002
8-other
Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation.
PMID 11917286·Semin Radiat Oncol·2002
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 511 STATE ST
OGDENSBURG, NY 13669 - Phone
- (315) 393-6290
Quick Facts
- NPI
- 1558953497
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 14
Are you this provider?
Claim Your Profile